In AML allogeneic hematopoietic stem cell transplantation (allo-HSCT) models, TIM-3 blockade may lead to activation of macrophages to eradicate AML stem cells and ameliorate disease (39, 83). This evidence concerns the gene HAVCR2 and acute myeloid leukemia.